NCCN Renal Cell Registry

Not Applicable

Completed

• Conditions: Renal Cell Carcinoma
• Interventions: Other: chart abstraction; Other: Educational Program

• Registration Number: NCT02677337
• Lead Sponsor: Duke University

Brief Summary

This study will consist of three parts: 1) a retrospective chart review of patients treated for mRCC from July 2013 until the start of the educational intervention; 2) an educational program for DCN community oncology providers and DCN community patients with mRCC, lasting 8 - 10 months, and 3) a second retrospective chart review of patients treated for mRCC starting at the time of the educational intervention until the intervention is completed.

Detailed Description

The initial retrospective cohort will serve as the pre-education control, and the second cohort will be the experimental group to assess the efficacy of the educational intervention to change care of patients with mRCC.

Chart Reviews. This study will begin with a multi-site chart review conducted at the Duke Cancer Network affiliated sites. The chart review will begin in late fall, 2015. The Duke Cancer Network team will perform chart abstraction for this study, with a goal of reviewing at least 60 charts of patients treated between July 2013 and October 2015.

The second data collection period will collect data on patients with mRCC seen at DCN sites after the date in fall 2015 when the educational intervention is rolled out. The target will again be at least 60 charts of patients treated during the time the educational intervention is actively available.

Study Timeline

• Study First Submitted: 2016-02-03
• Study First Submitted QC: 2016-02-04
• Study First Posted: 2016-02-09
• Study Start: 2016-03
• Primary Completion: 2016-12
• Study Completion: 2016-12
• Status Verified: 2017-02
• Last Update Submitted: 2017-02-15
• Last Update Posted: 2017-02-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• Oncology providers (physicians, nurse practitioners, physicians' assistants) at DCN affiliated sites will be invited to use the performance support system and participate in the online virtual tumor boards for CME credit.

Exclusion Criteria

• Non DCN affiliated sites providers

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Educational Program	chart abstraction	chart abstraction will be conducted post education intervention component.
Educational Program	Educational Program	chart abstraction will be conducted post education intervention component.

Primary Outcome Measures

Name	Time	Method
Assignment of patient to appropriate firstline treatment based on Heng Risk criterion	eight to ten months	Improvement in the percentage of patients receiving appropriately prescribed first line therapy for metastatic renal cell cancer (mRCC)

Secondary Outcome Measures

Name	Time	Method
Percentage of increase in duration of treatment with appropriate first line therapy	eight to ten months

Trial Locations

Locations (1)

Duke University Medical Center; 🇺🇸 Durham, North Carolina, United States